|
|
|
 |
| Location: Home -
Products - API Intermediates - API Intermediates
|
Fidaxomicin(Lipiarmycin)
| Catalogue No. : |
C13670 |
| Product Name: |
Fidaxomicin(Lipiarmycin) |
| Synonym: |
R-Tiacumicin B; Tiacumicin B; OPT-80; PAR-101;Clostomicin B1;Dificid |
| Chemical Name: |
3-(((6-Deoxy-4-O-(3,5-dichloro-2-ethyl-4,6-dihydroxybenzoyl)-2-O-methyl-b-D-mannopyranosyl)oxy)-methyl)-12(R)-[(6-deoxy-5-C-methyl-4-O-(2-methyl-1-oxopropyl)-b-D-lyxo-hexopyranosyl)oxy]-11(S)-ethyl-8(S)-hydroxy-18(S)-(1(R)-hydroxyethyl)-9,13,15-trimethyloxacyclooctadeca-3,5,9,13,15-pentaene-2-one |
| CAS No. : |
873857-62-6 |
| Structure : |
|
| Molecular Formula: |
C52H74Cl2O18 |
| Molecular Weight: |
1058.04 |
| Appearance: |
White solid |
| Solubility: |
Soluble in ethanol, methanol, DMF or DMSO. Limited water solubility |
| Purity: |
>99% |
| Usage: |
Fidaxomicin is a recently approved antibiotic with a confusing history dating back to its original isolation in 1975. Fidaxomicin is the major analogue of a family of macrocyclic lactones isolated independently by three different groups from cultures belonging to three different genera (Actinoplanes, Dactylosporangium and Micromonospora) known as lipiarmycin A3, tiacumicin B and clostomicin B1, respectively. Fidaxomicin is a narrow spectrum antibiotic with excellent activity against Gram positive bacteria, notably Clostridium difficile. Fidaxomicin acts in the gastrointestinal tract without undue disruption to gut microbial flora. |
|
| Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. As it is impossible for us to be informed about the patent situation in all countries, the liability for patent infringement is exclusively to be understood as buyer's risk. |
|
|
